nChroma Bio has received regulatory clearance in Hong Kong to initiate a Phase 1/2 clinical trial of its lead candidate CRMA-1001, marking the first...
Regeneron Pharmaceuticals and Tessera Therapeutics have formed a global partnership to develop and commercialise TSRA-196, Tessera’s lead in vivo Gene...
CRISPR Therapeutics has presented preclinical data showing that its investigational therapy CTX460 can correct the SERPINA1 Z (E342K) mutation...
2021 was a very successful year for CRISPR in the medical field. Much of the success comes down to gene editing without double-strand breaks,...
In this piece, we provide selected highlights from the 63rd American Society of Hematology annual meeting, held from December 11-14th 2021.
Some of the best links we picked up around the internet
Update on Allogene Therapeutics off-the-shelf CAR-T cancer therapies. This week’s gene-editing update looks at an investigational new drug (IND)...
Last week, we bought you our first IND update for a selection of gene-editing therapies currently under development for blood disorders. This week, we...
